Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams

• The NAVIFY Tumor Board solution is a new, cloud-based software solution that fundamentally changes the way oncology care teams prepare for, conduct and document clinical treatment decisions for cancer patients
• It supports care team collaboration and standardizes clinical workflow by aggregating all relevant patient data from multiple sources into one dashboard
• Positive feedback from US and EU tumor board pilot sites validate efficiency gains

Roche (SIX: RO, ROG; OTCQX:RHHBY), today announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. The solution fundamentally changes the way these meetings are organised and conducted. It is initially available in the US, UK, Germany, Spain, Sweden, and Switzerland.

Tumor board coordination is labour intensive and time consuming for health care providers with patients’ medical history, biomarkers, tumor information, radiology images, microscope slide images, pathology reports, and electronic medical record notes frequently having to be collected and organised manually.
The new NAVIFY Tumor Board solution streamlines and standardizes workflows by aggregating relevant patient data from these disparate sources into a workflow software solution that facilitates efficient team collaboration, reduces errors, and gives the care team more time to evaluate potential treatment options.
To facilitate interaction, the NAVIFY Tumor Board solution also allows remote participation of experts from outside the location during the meeting.

“Oncology care teams are now able to collaborate on the review of patient cases and tailor treatments to the individual with a higher degree of confidence and more efficiently,” said Roland Diggelmann, Chief Executive Officer, Roche Diagnostics. “At Roche, we are passionate about personalised healthcare and providing decision support that helps ensure that all available data is used to accelerate and optimise patient care.”

About NAVIFY

Roche Diagnostics is launching the NAVIFY brand demonstrating its commitment to provide healthcare professionals with digital decision support solutions that transform patient care. The NAVIFY portfolio’s first product is the NAVIFY Tumor Board solution, being launched today. The portfolio will in the near future, evolve rapidly to include additional decision support applications and workflow products that address challenges faced by healthcare providers as well as research and development applications.

Patient data security and privacy are of the highest priority for Roche. The NAVIFY Tumor Board solution is built on a secure cloud platform that is HIPAA compliant.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.